TABLE 3.
Results of the base-case analysis and subgroup analysis.
| Country | Regimen | LY | QALY | Cost, US$ | ICER ($/LY) | ICUR ($/QALY) |
|---|---|---|---|---|---|---|
| US | Placebo plus chemotherapy | 1.957 | 1.419 | 62,422 | - | - |
| Atezolizumab plus chemotherapy | 2.290 | 1.651 | 233,492 | 513,724 | 737,371 | |
| China | Placebo plus chemotherapy | 1.957 | 1.365 | 9,912 | - | - |
| Atezolizumab plus chemotherapy | 2.290 | 1.580 | 96,946 | 261,363 | 404,809 |
LY, life-year; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; ICUR, incremental cost–utility ratio.